Patient Flow in Hepatitis C Virus: Changing Treatment Dynamics in China
China has one of the most rapidly growing pharmaceutical markets in the world, as well as a vast, rapidly expanding prevalent population of Hepatitis C (HCV) patients. The key driver of the Chinese HCV market is the increase in the drug-treated population due to the introduction of novel HCV-specific therapies that will be combined in highly effective, all-oral IFN-free regimens. Combined with increasing access to medical care and a burgeoning middle class with growing economic clout, these factors promise fast growth and significant opportunity for multinational pharmaceutical companies.
Related Market Assessment Reports
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
